Pulse Biosciences Inc.
02/27/2026 | Press release | Distributed by Public on 02/27/2026 16:26
Management Change/Compensation (Form 8-K)
|
Item 5.02
|
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. |
On February 27, 2026, Kevin P. Danahy, the Chief Commercial Officer of Pulse Biosciences, Inc. (the "Company") gave notice that he was resigning from the Company, effective immediately. Mr. Danahy's resignation was not a result of any disagreement with the Company on any matter relating to its operations, policies, or practices, or to any issues regarding its accounting policies or practices. During his tenure at the Company, Mr. Danahy was an important part of senior management as well as the Company's early commercialization efforts, and we wish him well in his future endeavors.
Pulse Biosciences Inc. published this content on February 27, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on February 27, 2026 at 22:26 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]